DRUG NEWS: Docetaxel approved for prostate cancer

January 2005 
Volume 35  Number 1
Pages 29 - 29
  PDF Version Available!

© 2005 Lippincott Williams & Wilkins, Inc. Volume 35(1)             January 2005             p 29 Docetaxel approved for prostate cancer [DRUG NEWS: BREAST CANCER DRUG]

A mainstay for breast cancer treatment, docetaxel (Taxotere) has been approved by the FDA to treat prostate cancer too.

Given by injection in a regimen that includes prednisone, the drug may prolong the lives of men with advanced disease. In clinical trials, the treatment extended life for men with metastatic, hormone-refractory prostate cancer by about 2½ months, compared with a similar group receiving standard chemotherapy with mitoxantrone and prednisone.

Patients receive a docetaxel injection once every 3 weeks and prednisone daily. Possible adverse reactions include nausea, alopecia, bone marrow suppression, fluid retention, and peripheral neuropathy.

For more information, visit the FDA's Web site ...

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

Featured Jobs

Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member